ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN-merket, grunnlagt 2010 (forente stater), fra 496 tilknyttede merkevarer og 17479 konkurrerende merkevarer. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN er et merke fra BRISTOL-MYERS SQUIBB COMPANY, børsnotert i New York. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN kommer under Legemiddelprodusenter-bransjen.

ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN er et varemerke som tilhører BRISTOL-MYERS SQUIBB COMPANY (BMY) Nyheter

Internasjonalt innskudd : 2010 Bransje Legemiddelprodusenter

Alle nyhetene Marketscreener-logo
BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)

loader
Børs: Mer informasjon om BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN) Marketscreener-logo